Kevin manages the $46 million Connecticut BioScience Facilities Fund, which invests in the build-out of wet laboratory space. He has led CI’s investments in Affinimark Technologies, Cara Therapeutics, Discover Video, HistoRx (sold to Genoptix), Intelligent Clearing Network (ICN), Oil Purification Systems, Oxford Performance Materials, Precipio Diagnostics and Solais Lighting (sold to PowerSecure), and was on the board of Standing Stone, Inc. when it was sold to Alere, Inc. in May 2011.
Before joining CI, Kevin was director of the Office of Bioscience at the Connecticut Department of Economic and Community Development (DECD), where he led the organization’s efforts in bioscience business recruitment, client interaction, bioscience-related public policy strategy and day-to-day operations. While at DECD, Kevin also served as director of business recruitment in DECD’s Business Recruitment and Industry Clusters Division, negotiating relocation incentive packages for high-priority corporate development projects, including Pfizer’s clinical facility in New Haven and DST Output’s facility in South Windsor.
Best Advice Given